BioVie Inc.

NasdaqCM BIVI

BioVie Inc. Operating Income for the Trailing 12 Months (TTM) ending September 30, 2024: USD -25.43 M

BioVie Inc. Operating Income is USD -25.43 M for the Trailing 12 Months (TTM) ending September 30, 2024, a 46.03% change year over year. Operating income is the profit earned by a company from its normal business operations before interest and taxes are deducted.
  • BioVie Inc. Operating Income for the Trailing 12 Months (TTM) ending September 30, 2023 was USD -47.12 M, a -54.30% change year over year.
  • BioVie Inc. Operating Income for the Trailing 12 Months (TTM) ending September 30, 2022 was USD -30.54 M, a 78.68% change year over year.
  • BioVie Inc. Operating Income for the Trailing 12 Months (TTM) ending September 30, 2021 was USD -143.21 M, a -5,934.09% change year over year.
  • BioVie Inc. Operating Income for the Trailing 12 Months (TTM) ending September 30, 2020 was USD -2.37 M, a 12.46% change year over year.
Key data
Date Operating Income EBIT EBITDA Net Income
Market news
NasdaqCM: BIVI

BioVie Inc.

CEO Mr. Cuong Viet Do M.B.A.
IPO Date Sept. 18, 2020
Location United States
Headquarters 680 West Nye Lane
Employees 14
Sector Health Care
Industries
Biotechnology Clinical Trials Pharmaceuticals
Description

BioVie Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of drugs therapies in the United States. Its products in pipeline include BIV201, which completed Phase IIa clinical trial for the treatment of ascites due to chronic liver cirrhosis; and NE3107, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease and Phase I clinical trial for the treatment of Parkinson's disease. The company is also developing NE3107, which is in pre-clinical stage for the treatment of multiple myeloma and prostate cancer. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is based in Carson City, Nevada.

Similar companies

HOOK

HOOKIPA Pharma Inc.

USD 1.86

4.49%

INZY

Inozyme Pharma, Inc.

USD 1.51

-12.21%

MREO

Mereo BioPharma Group plc

USD 3.06

-8.38%

TERN

Terns Pharmaceuticals, Inc.

USD 4.57

-4.79%

ABOS

Acumen Pharmaceuticals, Inc.

USD 1.56

-1.89%

ELDN

Eledon Pharmaceuticals, Inc.

USD 3.71

-4.63%

DAWN

Day One Biopharmaceuticals, Inc.

USD 11.16

-3.46%

AMLX

Amylyx Pharmaceuticals, Inc.

USD 3.13

-1.57%

StockViz Staff

January 15, 2025

Any question? Send us an email